California's Solutions to Health Care

Chronic Disease Economic Impact (California, 2016):

• Direct healthcare spending on chronic illnesses totaled $112 billion.
• Including indirect costs (productivity losses and premature mortality), the total economic burden reached $378.3 billion.
• This $378.3 billion figure represents 14.5% of California's GDP.
• Cardiovascular conditions represent the largest slice of chronic disease spending.
• Over 61% of California adults are overweight or obese, driving 36% of chronic disease treatment costs.
• Demographic projections indicate the population aged 65+ will grow from 14% in 2016 to 23% within 20 years, disproportionately increasing chronic disease burdens.

Home Care Workforce Crisis:

• The California Employment Development Department projects a need to add 200,000 home care jobs by 2024 (a 36% increase).
• If full care needs are met, the state could require up to 600,000 additional workers by 2030, with some estimates reaching 3.2 million.
• Current turnover in the home care workforce stands at 33%.
• Institutional care is 30% to 40% more expensive than home-based care, yet home care options remain understaffed.
• In 2015, the median hourly wage for home care workers was $10.05, with an annual median salary of $14,000.
• 40.7% of home care workers rely on public programs for their own health insurance, and most lack employer-paid retirement or Social Security access.
• A CMMI-funded training pilot involving 6,000 home care providers resulted in reduced hospital stays, ER visits, and overall costs.

Prescription Drug Pricing and Innovation:

• Biologic medicines are increasingly viewed as essential solutions to rising disease costs, despite their high price tags, rather than the primary problem.
• Amgen notes that medicines account for 14–17% of total US medical spending, a figure consistent for decades.
• Cardiovascular disease costs are projected to rise from $600 billion to $900 billion by 2030.
• Alzheimer's disease is expected to cost society over $1 trillion by 2050.
• Industry partners (e.g., Amgen) are implementing risk-sharing agreements where manufacturers refund costs if patients suffer heart attacks while on medication or if cholesterol targets are not met.
• Amgen opposes direct price controls, arguing they stifle R&D; 95% of human clinical trials fail, requiring high-risk investment engines to function.
• The panel supports transparency legislation (like California's drug price reporting bill) but advocates for market-based value solutions over regulation.

Precision Medicine and Data Infrastructure:

• Only 62% of Americans are familiar with the term "precision medicine," despite its potential to treat individuals based on genomics, lifestyle, and environment.
• Current cancer drug utilization shows inefficiency: only 25% of patients benefit from prescribed drugs, meaning 75% of cancer drug spending is wasted.
• Targeted testing can yield significant savings; for example, KRAS gene testing for colorectal cancer could save $600 million annually.
• A BRCA test for breast cancer patients could reduce unnecessary chemotherapy by over 30%.
• The Obama administration's Precision Medicine Initiative aimed to aggregate data from one million Americans on an open platform to accelerate discovery.
• Current payment systems lag behind scientific capability, operating on "epidemiological averages" rather than individual patient needs (described as "Star Wars medicine in Flintstones healthcare").
• Only 25% of physicians feel confident making treatment decisions based on genomic data, and only 10% of doctors currently recommend such testing to patients.
• Manifest Med-X is creating health information exchanges in California to break down data silos between 60+ hospitals and payers, fostering pre-competitive collaboration.

Workforce and Community Health Models:

• Community health workers saved an estimated 165,000 lives in the US in 2015, with an economic value of up to $500 billion.
• Community health workers bridge gaps in cultural, linguistic, and physical access to care, particularly for populations with limited English proficiency.
• Barriers to scaling include antiquated payment models focused on volume rather than value.
• MACRA legislation is driving physician payment models toward quality measurement and alternative payment models (APMs).
• California faces specific challenges in closing care gaps due to its linguistic diversity, with some patients waiting six months for appointments due to a lack of linguistically competent providers.

Future Outlook and Strategic Priorities:

• Panelists agreed the transition from "break-fix" (volume-based) to "predict-prevent-protect" (value-based) models is critical.
• A robust federal budget and Medicaid expansion are seen as prerequisites for universal healthcare access.
• Key obstacles to progress include perverse financial incentives, political fragmentation, and a legal system that encourages defensive medicine.
• Empowering patient voices is identified as a necessary step to override discrete industry interests and drive holistic system change.
• There is a consensus that California must lead the nation by establishing a common information backbone and ambitious payment strategies that support home and community care.